Lantz Financial LLC Acquires 94 Shares of Eli Lilly and Company (NYSE:LLY)

Lantz Financial LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 9.3% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 1,110 shares of the company’s stock after buying an additional 94 shares during the period. Lantz Financial LLC’s holdings in Eli Lilly and Company were worth $521,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of LLY. Silicon Valley Capital Partners acquired a new position in shares of Eli Lilly and Company during the first quarter valued at about $25,000. Bogart Wealth LLC increased its position in Eli Lilly and Company by 193.3% in the 1st quarter. Bogart Wealth LLC now owns 88 shares of the company’s stock valued at $30,000 after buying an additional 58 shares in the last quarter. Laffer Tengler Investments bought a new position in Eli Lilly and Company in the first quarter worth approximately $33,000. Raleigh Capital Management Inc. grew its stake in Eli Lilly and Company by 156.4% in the first quarter. Raleigh Capital Management Inc. now owns 100 shares of the company’s stock valued at $34,000 after acquiring an additional 61 shares during the period. Finally, Tanglewood Legacy Advisors LLC bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $37,000. Institutional investors and hedge funds own 81.38% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on LLY shares. Royal Bank of Canada lifted their price target on shares of Eli Lilly and Company from $490.00 to $580.00 and gave the company an “outperform” rating in a research report on Tuesday, August 8th. The Goldman Sachs Group boosted their target price on shares of Eli Lilly and Company from $385.00 to $470.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 9th. HSBC began coverage on shares of Eli Lilly and Company in a research report on Friday, July 14th. They issued a “buy” rating and a $560.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $630.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, September 5th. Finally, Truist Financial lifted their target price on Eli Lilly and Company from $525.00 to $600.00 and gave the company a “buy” rating in a research report on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating and twenty have assigned a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $532.78.

Eli Lilly and Company Stock Performance

NYSE:LLY traded up $3.36 during trading hours on Tuesday, reaching $574.64. The stock had a trading volume of 235,420 shares, compared to its average volume of 3,021,886. The stock has a market cap of $545.50 billion, a P/E ratio of 79.44, a price-to-earnings-growth ratio of 2.37 and a beta of 0.32. The stock has a 50 day simple moving average of $512.56 and a 200 day simple moving average of $439.28. The company has a debt-to-equity ratio of 1.63, a quick ratio of 0.87 and a current ratio of 1.13. Eli Lilly and Company has a 12-month low of $296.32 and a 12-month high of $601.84.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.98 by $0.13. The business had revenue of $8.31 billion for the quarter, compared to analysts’ expectations of $7.58 billion. Eli Lilly and Company had a return on equity of 65.00% and a net margin of 22.01%. The firm’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same period in the previous year, the business posted $1.25 EPS. On average, research analysts forecast that Eli Lilly and Company will post 9.84 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 15th were paid a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date of this dividend was Monday, August 14th. Eli Lilly and Company’s payout ratio is currently 62.87%.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 11,760 shares of the stock in a transaction on Wednesday, June 28th. The stock was sold at an average price of $465.41, for a total transaction of $5,473,221.60. Following the sale, the insider now owns 101,237,050 shares in the company, valued at $47,116,735,440.50. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, major shareholder Lilly Endowment Inc sold 11,760 shares of the firm’s stock in a transaction that occurred on Wednesday, June 28th. The shares were sold at an average price of $465.41, for a total value of $5,473,221.60. Following the completion of the transaction, the insider now directly owns 101,237,050 shares in the company, valued at $47,116,735,440.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Alonzo Weems sold 1,148 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $590.98, for a total transaction of $678,445.04. Following the transaction, the executive vice president now directly owns 7,760 shares of the company’s stock, valued at approximately $4,586,004.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 976,153 shares of company stock worth $21,080,192,113. Corporate insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.